G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

PURPOSE: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer Res Treat
Hlavní autoři: Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2020
Témata:
Preclinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103015/
https://ncbi.nlm.nih.gov/pubmed/32130619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05575-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky